Phase II study of teniposide in advanced breast cancer

In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therape...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 1990-01, Vol.25 (6), p.463-464
Hauptverfasser:	BOAS, J, RASMUSSEN, D, HANSEN, O. P, ENGELHOLM, S. A, DOMBERNOWSKY, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy Drug Administration Schedule Drug Evaluation Female Humans Infusions, Intravenous Leukopenia - chemically induced Medical sciences Middle Aged Pharmacology. Drug treatments Podophyllotoxin - analogs & derivatives Teniposide - administration & dosage Teniposide - adverse effects Teniposide - therapeutic use Thrombocytopenia - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer.
ISSN:	0344-5704 1432-0843
DOI:	10.1007/BF00686061